2017
Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial)
Serrao GW, Lansky AJ, Mehran R, Stone GW. Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). The American Journal Of Cardiology 2017, 121: 678-683. PMID: 29394998, DOI: 10.1016/j.amjcard.2017.12.004.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntithrombinsBiomarkersCoronary AngiographyFemaleHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPredictive Value of TestsRecombinant ProteinsRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionStentsStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionLeft ventricular ejection fractionPrimary PCIAcute Myocardial Infarction trialMyocardial Infarction trialElevation myocardial infarctionHarmonizing OutcomesLVEF improvementMyocardial infarctionLower baseline left ventricular ejection fractionLeft ventricular ejection fraction improvementBaseline left ventricular ejection fractionGlycoprotein IIb/IIIa inhibitorsVentricular ejection fraction improvementMyocardial Infarction 3 flowIIb/IIIa inhibitorsEjection fraction improvementHalf of patientsPercutaneous coronary interventionVentricular ejection fractionPredictors of improvementPrespecified substudyPrimary stentingAngiographic predictors
2016
Impact of gender on infarct size, ST-segment resolution, myocardial blush and clinical outcomes after primary stenting for acute myocardial infarction: Substudy from the EMERALD trial
Ng VG, Mori K, Costa RA, Kish M, Mehran R, Urata H, Saku K, Stone GW, Lansky AJ. Impact of gender on infarct size, ST-segment resolution, myocardial blush and clinical outcomes after primary stenting for acute myocardial infarction: Substudy from the EMERALD trial. International Journal Of Cardiology 2016, 207: 269-276. PMID: 26808991, DOI: 10.1016/j.ijcard.2016.01.013.Peer-Reviewed Original ResearchConceptsPrimary percutaneous interventionAcute myocardial infarctionST-segment resolutionInfarct sizeMyocardial infarctionST-segment elevation acute myocardial infarctionPrimary PCIPrior acute myocardial infarctionElevation acute myocardial infarctionComplete ST resolutionSmaller infarct sizeDistal protection devicesSmall vessel sizeGender-specific factorsDistal protectionEMERALD trialLAD infarctsMore hypertensionWorse comorbiditiesMidterm outcomesPrimary stentingSegment resolutionAMI patientsClinical outcomesST resolution
2010
Nitinol Stent Implantation Versus Balloon Angioplasty for Lesions in the Superficial Femoral Artery and Proximal Popliteal Artery
Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Jaff MR. Nitinol Stent Implantation Versus Balloon Angioplasty for Lesions in the Superficial Femoral Artery and Proximal Popliteal Artery. Circulation Cardiovascular Interventions 2010, 3: 267-276. PMID: 20484101, DOI: 10.1161/circinterventions.109.903468.Peer-Reviewed Original ResearchConceptsSuperficial femoral arteryProximal popliteal arteryTarget lesion revascularizationAngioplasty groupStent groupFemoral arteryLesion revascularizationPopliteal arteryBalloon angioplastyPrimary patencyAngiographic resultsBetter acute angiographic resultsProvisional stent implantationSuboptimal angiographic resultsEndovascular treatment strategiesFlow-limiting dissectionPercutaneous transluminal angioplastyAcute angiographic resultsTotal lesion lengthLoss of patencySuperficial femoral artery (SFA) stentingSelf-expanding nitinolBailout stentingIntermittent claudicationPrimary stenting
2009
Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction
RABBANI LE, IYENGAR S, DANGAS GD, GRINES CL, COX DA, GARCIA E, TCHENG JE, GRIFFIN JJ, GUAGLIUMI G, STUCKEY T, TURCO M, STANT J, FAHY M, LANSKY AJ, MEHRAN R, STONE GW. Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. Journal Of Interventional Cardiology 2009, 22: 378-384. PMID: 19496901, DOI: 10.1111/j.1540-8183.2009.00474.x.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinConfidence IntervalsDrug Therapy, CombinationDrug-Eluting StentsFemaleHumansImmunoglobulin Fab FragmentsKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPlatelet Aggregation InhibitorsPreoperative CarePyridinesTime FactorsConceptsMajor adverse cardiovascular eventsAcute myocardial infarctionTarget vessel revascularizationIschemic target vessel revascularizationPrimary stentingThienopyridine administrationLoading doseTH patientsStent implantationMyocardial infarctionClopidogrel loading doseAdverse cardiovascular eventsSuperior clinical outcomesBare-metal stentingAbciximab useCADILLAC trialCardiovascular eventsVessel revascularizationClinical outcomesMetal stentingProcedural characteristicsOperator's discretionPatientsStentingCore lab
2008
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial
Lansky AJ, Tsuchiya Y, Brener M, Mehran R, Cristea E, Pietras C, Grines CL, Cox DA, Garcia E, Tcheng JE, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Leon MB, Moses J, Stone GW. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial. Catheterization And Cardiovascular Interventions 2008, 72: 917-924. PMID: 19016469, DOI: 10.1002/ccd.21714.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinClopidogrelCoronary AngiographyDrug Therapy, CombinationEuropeFemaleHemorrhageHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionMyocardial IschemiaPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentStentsThrombosisTiclopidineTime FactorsTreatment OutcomeUnited StatesConceptsAcute myocardial infarctionPrimary stentingCADILLAC trialRecurrent ischemiaSevere bleedingMyocardial infarctionEfficacy of clopidogrelMore recurrent ischemiaTIMI 0/1 flowSimilar clinical outcomesTiclopidine treatmentAngiographic characteristicsClopidogrel useIndependent predictorsClinical outcomesMultivariable analysisRandomized trialsStent thrombosisStent implantationOperator's discretionClopidogrelStentingPatientsTiclopidineRelative safety
2005
Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
Lansky A, Piedras C, Costa R. Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. ACC Current Journal Review 2005, 14: 44-45. DOI: 10.1016/j.accreview.2005.08.053.Peer-Reviewed Original ResearchGender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction
Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW. Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction. Circulation 2005, 111: 1611-1618. PMID: 15811868, DOI: 10.1161/01.cir.0000160362.55803.40.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionPrimary stentingAddition of abciximabBody surface areaCADILLAC trialMyocardial infarctionRisk factorsFemale genderIschemic target vessel revascularizationLower body surface areaMajor adverse cardiac eventsOverall adverse outcomesTIMI grade 3Adverse cardiac eventsTarget vessel revascularizationClinical risk factorsComorbid risk factorsInterventional treatment strategiesImportant independent determinantHigh mortality rateMACE ratePrimary angioplastyCardiac eventsSymptom onsetIndependent predictors
2004
Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial)
Dangas G, Aymong ED, Mehran R, Tcheng JE, Grines CL, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Lansky AJ, Stone GW, Investigators F. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). The American Journal Of Cardiology 2004, 94: 983-988. PMID: 15476608, DOI: 10.1016/j.amjcard.2004.06.050.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionPercutaneous coronary interventionAcute myocardial infarctionMajor adverse cardiac eventsAdverse cardiac eventsEarly thrombosisAbciximab usePrimary stentingPrimary angioplastyCardiac eventsBalloon angioplastyMyocardial infarctionBalloon diameterLate Angioplasty Complications (CADILLAC) trialRepeat target vessel revascularizationRepeat coronary angioplastyTarget vessel revascularizationHigh rateControlled AbciximabVessel revascularizationAngiographic morphologyClinical determinantsComplications TrialControl patientsCoronary intervention
2003
Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction
Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW. Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction. Circulation 2003, 108: 1316-1323. PMID: 12939213, DOI: 10.1161/01.cir.0000087601.45803.86.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdultAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCombined Modality TherapyCoronary AngiographyEndpoint DeterminationFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexStentsTreatment OutcomeConceptsComposite end pointTarget vessel revascularizationIschemia-driven target vessel revascularizationPrimary percutaneous coronary interventionAbciximab treatmentPercutaneous coronary interventionAcute myocardial infarctionMyocardial infarctionCoronary interventionEnd pointPlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsInfarct artery reocclusionPrespecified secondary analysisEvent-free survivalFactorial design trialLack of effectAbciximab useAngiographic substudyCADILLAC trialTVR ratesPrimary angioplastyPrimary stentingAngiographic outcomes
2002
Primary stenting optimizes the outcome of women with acute myocardial infarction: results from the CADILLAC trial
Lansky A, Grines C, Desai K, Cristea E, Corral M, Cox D, Gedney S, Griffin J, Stuckey T, Garcia E, Rutherford B, Stone G. Primary stenting optimizes the outcome of women with acute myocardial infarction: results from the CADILLAC trial. Journal Of The American College Of Cardiology 2002, 39: 39. DOI: 10.1016/s0735-1097(02)80165-6.Peer-Reviewed Original ResearchDoes optimal or stent-like PTCA provide equivalent outcomes compared to primary stenting in acute myocardial infarction? Early and late results from the CADILLAC trial
Cox D, Grines C, Garcia E, Stuckey T, Tcheng J, Guagliumi G, Johnson A, Lansky A, Griffin J, Stone G. Does optimal or stent-like PTCA provide equivalent outcomes compared to primary stenting in acute myocardial infarction? Early and late results from the CADILLAC trial. Journal Of The American College Of Cardiology 2002, 39: 337. DOI: 10.1016/s0735-1097(02)81517-0.Peer-Reviewed Original Research